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Abstract
IMPORTANCE HIV-associated chronic lung disease (HCLD) in children is associated with small
airways disease, is common despite antiretroviral therapy (ART), and is associated with substantial
morbidity. Azithromycin has antibiotic and immunomodulatory activity and may be effective in
treating HCLD through reducing respiratory tract infections and inflammation.
OBJECTIVE To determine whether prophylactic azithromycin is effective in preventing worsening
of lung function and in reducing acute respiratory exacerbations (AREs) in children with HCLD
taking ART.
DESIGN, SETTING, AND PARTICIPANTS This double-blind, placebo-controlled, randomized clinical
trial (BREATHE) was conducted between 2016 and 2019, including 12 months of follow-up, at
outpatient HIV clinics in 2 public sector hospitals in Malawi and Zimbabwe. Participants were
randomized 1:1 to intervention or placebo, and participants and study personnel were blinded to
treatment allocation. Participants included children aged 6 to 19 years with perinatally acquired HIV
and HCLD (defined as forced expiratory volume in 1 second [FEV1] z score < −1) who were taking ART
for 6 months or longer. Data analysis was performed from September 2019 to April 2020.
INTERVENTION Once-weekly oral azithromycin with weight-based dosing, for 48 weeks.
MAIN OUTCOMES AND MEASURES All outcomes were prespecified. The primary outcome was the
mean difference in FEV1 z score using intention-to-treat analysis for participants seen at end line.
Secondary outcomes included AREs, all-cause hospitalizations, mortality, and weight-for-age z score.
RESULTS A total of 347 individuals (median [interquartile range] age, 15.3 [12.7-17.7] years; 177 boys
[51.0%]) were randomized, 174 to the azithromycin group and 173 to the placebo group; 162
participants in the azithromycin group and 146 placebo group participants had a primary outcome
available and were analyzed. The mean difference in FEV1 z score was 0.06 (95% CI, −0.10 to 0.21;
P = .48) higher in the azithromycin group than in the placebo group, a nonsignificant difference. The
rate of AREs was 12.1 events per 100 person-years in the azithromycin group and 24.7 events per 100
person-years in the placebo groups (hazard ratio, 0.50; 95% CI, 0.27 to 0.93; P = .03). The
hospitalization rate was 1.3 events per 100 person-years in the azithromycin group and 7.1 events per
100 person-years in the placebo groups, but the difference was not significant (hazard ratio, 0.24;
95% CI, 0.06 to 1.07; P = .06). Three deaths occurred, all in the placebo group. The mean weight-
for-age z score was 0.03 (95% CI, −0.08 to 0.14; P = .56) higher in the azithromycin group than in the




Question What is the effect of weekly
azithromycin on morbidity in children
with HIV-associated chronic
lung disease?
Findings In this randomized clinical trial
that included 347 children aged 6 to 19
years, azithromycin did not improve
lung function. The rate of acute
respiratory exacerbations was 12.1
events per 100 person-years in the
azithromycin group and 24.7 events per
100 person-years in the control group;
the hospitalization rate was 1.3 events
per 100 person-years in the
azithromycin group and 7.1 events per
100 person-years in the placebo group.
Meaning These findings suggest that
prophylactic azithromycin has no effect
on lung function in children with
HIV-associated chronic lung disease but




Author affiliations and article information are
listed at the end of this article.
Open Access. This is an open access article distributed under the terms of the CC-BY License.
JAMA Network Open. 2020;3(12):e2028484. doi:10.1001/jamanetworkopen.2020.28484 (Reprinted) December 17, 2020 1/14
Downloaded From: https://jamanetwork.com/ by a Norwegian Institute of Public Health User  on 01/25/2021
Abstract (continued)
CONCLUSIONS AND RELEVANCE In this randomized clinical trial specifically addressing childhood
HCLD, once-weekly azithromycin did not improve lung function or growth but was associated with
reduced AREs; the number of hospitalizations was also lower in the azithromycin group but the
difference was not significant. Future research should identify patient groups who would benefit
most from this intervention and optimum treatment length, to maximize benefits while reducing the
risk of antimicrobial resistance.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02426112
JAMA Network Open. 2020;3(12):e2028484. doi:10.1001/jamanetworkopen.2020.28484
Introduction
Antiretroviral therapy (ART) and cotrimoxazole prophylaxis have resulted in a dramatic reduction in
mortality among children with HIV globally.1 However, studies in the ART era in sub-Saharan Africa,
where 90% of children with HIV live, have demonstrated that approximately 30% of perinatally
HIV-infected older children and adolescents have chronic lung disease.2,3
In the pre-ART era, the most common cause of HIV-associated chronic lung disease (HCLD) was
lymphoid interstitial pneumonitis, a condition that responds well to ART and is now rarely seen in
clinical practice.4,5 HCLD remains highly prevalent among children in sub-Saharan Africa despite ART
but is a clinical entity distinct from that in the pre-ART era. The typical clinical picture is that of chronic
cough, hypoxia, breathlessness, and substantially reduced exercise tolerance.3,6,7 Lung function is
commonly impaired, with an obstructive irreversible pattern, and abnormalities are subtle on
radiographs.3,8,9 The predominant findings on computed tomography are mosaic decreased
attenuation9-11 consistent with constrictive obliterative bronchiolitis (OB).12,13
No association has been observed between abnormal lung function and ART use or duration,
and HCLD is therefore likely unresponsive to ART once established.14,15 Despite being common, there
is no evidence base to guide management of childhood HCLD, often resulting in presumptive
treatment for tuberculosis.16
Azithromycin (AZM) has bacteriostatic activity against the most common respiratory bacterial
pathogens, as well as a robust immunomodulatory effect. Specifically, AZM has direct activity on
airway epithelial cells to maintain their function and reduce mucus secretion.17 These characteristics
have resulted in AZM being used to treat a variety of chronic lung diseases.18-20 OB most commonly
occurs as a consequence of respiratory tract infections, with development closely associated with
severe viral infections in the early years of life.12,21 HIV is associated with both a high incidence of
respiratory infections and chronic systemic immune activation, despite ART.22-24 OB in the context
of HIV infection results from inflammation either due to HIV or as a sequelae of respiratory infections,
which consequently leads to aberrant fibroproliferative remodeling and fibrosis of the small
airways.12 This provides the rationale for testing the efficacy of AZM in patients with HCLD. We
conducted a randomized clinical trial to test the hypothesis that AZM is effective in preventing
worsening of lung function and in reducing acute respiratory exacerbations (AREs) in children and
adolescents with HCLD who are receiving ART.
Methods
Study Design
The Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease
in HIV-Infected Children (BREATHE) trial was a double-blind, placebo-controlled, randomized clinical
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trial conducted in Malawi and Zimbabwe. The trial protocol is available in Supplement 1, and baseline
characteristics of the participants have been published elsewhere.25,26
Ethical approval was granted by the Malawi College of Medicine research ethics committee, the
Medical Research Council of Zimbabwe, the Biomedical Research and Training Institute institutional
review board in Zimbabwe, the London School of Hygiene and Tropical Medicine ethics committee,
the University of Cape Town research ethics committee, and the Regional Ethics Committee for
Medical and Health Research in Norway. Written informed consent was sought from the guardian,
and age-appropriate assent was sought from the participant (for those aged <18 years); those aged 18
years and older consented independently. This study follows the Consolidated Standards of
Reporting Trials (CONSORT) reporting guideline.
Participants
Individuals aged 6 to 19 years attending outpatient HIV clinics at 2 public sector hospitals in Harare,
Zimbabwe, and Blantyre, Malawi, were eligible for enrollment if mother-to-child HIV transmission
was the most likely source of infection and if the following criteria were met: (1) patients had been
taking first-line or second-line ART for at least 6 months; (2) patients had HCLD, defined as forced
expiratory volume in 1 second (FEV1) z score less than −1.0 (after a protocol change in January 2017,
to increase generalizability, from z score < −1.64 in the original protocol; individuals with an FEV1 z
score between −1.0 and −1.64 before the protocol change were invited for rescreening) and lack of
reversibility (<12% improvement in FEV1) with salbutamol (200 μg) inhaled using a spacer; (3)
patients had a stable home address; (4) patients had been disclosed their HIV status (for those aged
12 years); and (5) patients had a guardian able to provide consent (for those aged <18 years).
Exclusion criteria were having a condition that could be fatal during the study period, acute
respiratory tract infection or tuberculosis at screening, pregnancy or breastfeeding, history of cardiac
arrhythmia, a prolonged corrected QT (QTc) interval (>440 ms in male patients and >460 ms in
female patients), creatinine clearance less than 30 ms/minute, alanine aminotransferase more than
2 times the upper limit of normal, known macrolide hypersensitivity, and use of drugs known to
prolong the QTc interval. Tuberculosis screening was performed using the Xpert MTB/RIF assay
(Cepheid) on 1 sputum sample obtained either spontaneously or through induction.
Trial Procedures
Participants were randomly assigned in a 1:1 allocation ratio to receive either an oral weekly dose of
AZM or placebo tablets of identical appearance for 48 weeks. Dosing was by participant weight: 10 to
19.9 kg, 250 mg; 20 to 29.9 kg, 500 mg; 30 to 39.9 kg, 750 mg; and 40 kg or more, 1250 mg. The
randomization schedule and allocation list were generated by an independent statistician.
Randomization was performed with block sizes ranging from 2 to 6 participants and was stratified by
country. Participants and study personnel, including laboratory personnel and staff conducting
outcome assessments, were blinded to treatment allocation.
After enrollment, participants were followed up at 2 weeks and every 12 weeks thereafter. At
each visit, participants were asked about symptoms, adverse effects, use of antibiotics or other
drugs, and adherence. The required number of tablets, with a buffer of 2 weeks, was dispensed by
pharmacists at baseline and at the 2-, 12-, 24- and 36-week visits. We defined an adherent participant
as not missing, on average, more than 2 of the 12 (13 in the first period) dispensed doses, as assessed
by pill count, splitting time in the study into 4 12-week periods, as per visit and study medication
dispensing schedule.
Participants were instructed to attend the clinic if they developed acute symptoms, which were
graded using Division of AIDS (DAIDS) criteria. For diarrheal episodes of DAIDS severity grade 3, a
rectal swab and Clostridium difficile rapid test was taken (C. Diff Quick Check Complete; Alere), and if
the results were positive, the patient was treated with metronidazole for 7 days. AREs were defined
as new or worsening respiratory symptoms with or without symptoms and signs of an infection as
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assessed by a clinician. Participants were specifically counseled to present to the study clinic if they
developed respiratory symptoms for assessment and were encouraged to do so at every study visit.
Participants with a suspected ARE had sputum and nasal swabs taken and were treated with
amoxicillin-clavulanate for 10 days; if there was no improvement, a chest radiograph was obtained
and sputum culture for tuberculosis was performed. For febrile episodes, blood cultures and malaria
testing (using microscopy or rapid diagnostic tests) were performed with management according to
national guidelines. For other acute symptoms, management was at the discretion of the treating
clinician.
The primary outcome was assessed at 48 weeks (window period, 44-52 weeks). The initial trial
protocol stipulated follow-up to and measurement of FEV1 z score at 72 weeks as a secondary end
point to examine the durability of the intervention’s effect. However, because of slow recruitment,
the enrollment period was increased, and follow-up of all participants beyond 48 weeks was
therefore not feasible.
Outcomes
All outcomes were prespecified. The primary outcome was FEV1 z score at 48 weeks, calculated using
the African American module of the Global Lung Function Initiative 2012 reference equations.27 The
secondary outcomes were time to first ARE and number of AREs, death, all-cause hospitalization,
infectious episodes (Salmonella typhi, gastroenteritis, or malaria), and weight-for-age z score
(calculated using the British 1990 reference equations).28 All hospitalizations (defined as a period of
stay in a hospital >24 hours) were recorded whether or not participants visited the study clinic. These
were obtained through a combination of self-report and confirmation from patient-held records.
Statistical Analysis
The study was designed to detect a standardized mean difference in FEV1 z score between trial
groups of 0.32 SD with 80% statistical power and a significance level of P < .05, assuming a mean
(SD) in the control group of −2.04 (0.82) and a difference in means of 0.26. Available data from 300
participant assessments at 48 weeks were required for this.
Analyses were performed using Stata statistical software version 16.0 (StataCorp) following a
prespecified analysis plan (Supplement 1). All randomized participants were included, using
intention-to-treat principles. All analyses were adjusted for trial site and for baseline factors agreed
to be unbalanced between groups by trial investigators before data analysis. Linear regression was
used to analyze quantitative outcomes as adjusted mean differences (AMDs), additionally adjusted
for their comparable value at baseline. The normality of residuals was assessed with quantile-quantile
and kernel density plots. Homoscedasticity was assessed visually using the Cook-Weisburg test, and
robust SEs were used when there was evidence of heteroscedasticity.
Per-protocol analyses were conducted for participants who adhered to their randomized
treatment. Prespecified subgroup and sensitivity analyses (exclusion of participants who were found
after randomization but before data analysis, on recalculating enrollment FEV z score to account for
anomalies in recorded height, to not meet the FEV1 inclusion criteria) and post hoc sensitivity analysis
(multiple imputation for FEV1 z score for those with missing outcome data except deaths; see the
eAppendix in Supplement 2) were performed for the primary outcome.
Event outcomes were analyzed using time-to-event methods. Participants were censored at
date of death, date of withdrawal, date of last study visit (if lost to follow-up), or at 49 weeks after
commencing study medication. Cumulative incidence curves were generated, and Cox regression
and 2-sided Wald tests were used to compare trial groups, with robust SEs to account for multiple
event data. The proportional hazards assumption was assessed using Schoenfeld residuals. Data
analysis was performed from September 2019 to April 2020.
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Results
Characteristics of Participants
Between June 15, 2016, and September 4, 2018, 1585 individuals were assessed for eligibility, with
419 (26.4%) meeting lung function eligibility criteria. A total of 347 participants were enrolled and
randomly assigned (173 to receive AZM and 174 to receive placebo) (Figure 1). We included in the
analysis 11 participants (7 in the AZM group and 4 in the placebo group) found after randomization to
not meet the FEV1 inclusion criteria.
Participants had a median (interquartile range [IQR]) age of 15.3 (12.7-17.7) years, and 177
(51.0%) were boys. The mean (SD) FEV1 z score at baseline was −2.00 (0.75) and was comparable
between trial groups (−2.01 [0.76] in the AZM group vs −2.00 [0.74] in the placebo group). By
chance, we observed differences between trial groups in the distributions of age, sex, and HIV viral
load, and so all analyses estimating intervention effects were adjusted for these factors, with
age-defined cutoffs based on O’Leary et al29 (Table 1).
Study Medication
Study medication was stopped after a median (IQR) of 27 (10-38) weeks for 7 participants per
protocol; 3 participants became pregnant, 3 participants had a prolonged QTc interval (2 in the
placebo group and 1 in the AZM group; all 3 were asymptomatic with no history of cardiac disease),
Figure 1. Participant Enrollment Flowchart
1585
63
Individuals assessed for eligibility on nonclinical criteria








Received ≥1 dose of placebo
1603 Spirometry attempted











Unable to perform spirometry
FEV1 z score out of eligible range
162 Included in analysis of primary outcome
11 Excluded from primary outcome analysis









Assessed after 52 wk
Died
Missed 12-mo spirometry assessment
Pregnancy
146 Included in analysis of primary outcome
28 Excluded from primary outcome analysis









Assessed after 52 wk
Died











Eligible to continue screening
AZM indicates azithromycin; and FEV1, forced
expiratory volume in 1 second.
JAMA Network Open | Pulmonary Medicine Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease
JAMA Network Open. 2020;3(12):e2028484. doi:10.1001/jamanetworkopen.2020.28484 (Reprinted) December 17, 2020 5/14
Downloaded From: https://jamanetwork.com/ by a Norwegian Institute of Public Health User  on 01/25/2021
and 1 experienced a drug rash that was later determined to be unrelated to the trial drug. Adherence
was higher in the AZM group than in the placebo group (127 participants [73.4%] vs 117 participants
[67.2%]). AZM was not taken by any study participant during the study period, other than as a trial
drug by participants in the intervention group.
Follow-up and Outcomes
The primary outcome was assessed for 308 participants (88.8%), with fewer assessed in the placebo
group than in the AZM group (146 participants [83.9%] vs 162 participants [93.6%]) (eTable 1 in
Supplement 2). Baseline characteristics were similar between participants with and without primary
outcome data, except that those without outcome data were more likely to be female and were
slightly older (eTable 2 in Supplement 2).
Table 1. Characteristics of the Participants at Baseline
Characteristics
Participants, No. (%)
AZM group (n = 173) Placebo group (n = 174)
Demographic characteristics
Age, median (IQR), y 14.7 (12.6-16.8) 15.8 (13.0-18.1)
Female 80 (46.2) 90 (51.7)
Currently in schoola 146 (84.4) 139 (79.9)
HIV characteristics
Age at diagnosis, median (IQR), y 7.2 (3.5-9.9) 8.3 (5.2-11.1)
Cotrimoxazole prophylaxis 157 (90.7) 156 (89.7)
Duration taking antiretroviral therapy, median (IQR), y 5.9 (3.8-9.0) 6.4 (3.9-8.2)
HIV viral load log10 copies/mL, median (IQR)a 2.5 (1.6-4.0) 2.7 (1.7-4.1)
HIV viral load <1000 copies/mLa 100 (58.5) 94 (54.0)
CD4 cell count/mm3, median (IQR) 601 (417-784) 550 (325-779)
Lung function characteristics, mean (SD)
FEV1 z score −2.01 (0.76) −2.00 (0.74)
FEV1, L 1.59 (0.50) 1.71 (0.53)
FEV1, % 73.3 (10.3) 73.6 (10.2)
FVC z scorea −1.77 (0.97) −1.71 (0.89)
FVC, L 1.89 (0.59) 2.04 (0.63)
FVC, %a 77.8 (12.0) 78.4 (11.0)
FEV1:FVC ratio z scorea −0.66 (1.14) −0.74 (1.13)
FEV1:FVC ratioa 0.85 (0.08) 0.84 (0.08)
Clinical characteristics
Weight-for-age z score, mean (SD) −2.23 (1.43) −2.07 (1.50)
Underweightb 98 (56.7) 83 (47.7)
Height-for-age z score, mean (SD) −2.16 (1.18) −2.04 (1.24)
Stuntedb 95 (54.9) 80 (46.0)
History of tuberculosis 58 (33.5) 39 (22.4)
Admitted for chest problems in last year 3 (1.7) 3 (1.7)
Current cough 13 (7.5) 18 (10.3)
Coughing up sputumc 7 (4.0) 17 (9.8)
Shortness of breath 5 (2.9) 1 (0.6)
Respiratory rate, mean (SD), breaths/min 22.2 (3.0) 22.6 (3.2)
Abnormal respiratory rated 67 (38.7) 85 (48.9)
Oxygen saturation, mean (SD), %a 96.7 (3.0) 96.7 (2.4)
Oxygen saturation <92% 6 (3.5%) 11 (6.3%)
Heart rate, mean (SD), beats/mina 87.6 (12.5) 85.6 (11.6)
Abnormal heart rated 6 (3.5%) 8 (4.6%)
Shuttle walk duration, mean (SD), min:sa 10:26 (1:56) 10:49 (2:03)
Abbreviations: AZM, azithromycin; FEV1, forced
expiratory volume in 1 second; FVC, forced vital
capacity; IQR, interquartile range.
a Values were missing for currently attending school (1
patient in the AZM group and 3 patients in the
placebo group), HIV viral load (2 patients in the AZM
group), and FVC (3 patients in the AZM group and 5
patients in the placebo group).
b Denotes a z score less than −2.
c This question was asked for those with current
cough only.
d Age-defined cutoffs were based on data from
O’Leary et al.29
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The mean (SD) values of the primary outcome, FEV1 z score, were −1.90 (0.90) in the AZM
group and −1.95 (0.91) in the placebo group. The AMD was 0.06 (95% CI using robust SEs, −0.10 to
0.21; P = .48) higher in the AZM group than in the placebo group, a nonsignificant difference. The test
for the homoscedasticity assumption using the Cook-Weisburg test gave χ 21 = 6.4 and P = .01 before
robust SEs were applied. On the prespecified per-protocol analysis, the AMD was 0.14 (95% CI, −0.02
to 0.29; P = .08); under prespecified sensitivity analysis excluding the 11 participants with baseline
FEV1 z score greater than −1, the AMD was 0.07 (95% CI −0.08 to 0.23; P = .36). Under post hoc
multiple imputation of outcome data, the AMD was 0.05 (95% CI, −0.11 to 0.20; P = .54).
For assessment of secondary event outcomes, the median (IQR) follow-up period was 49
(49-49) weeks and the total follow-up time was 157 person-years in the AZM group and 154 person-
years in the placebo group. AREs occurred in 16 participants (9.2%) in the AZM group (10.8 first
events and 12.1 total events per 100 person-years) and 30 participants (17.2%) in the placebo group
(21.7 first events and 24.7 total events per 100 person-years) (Figure 2A and B and Table 2). The
hazard ratio in the AZM group compared with the placebo group for first ARE was 0.50 (95% CI,
0.27-0.92; P = .03) and the hazard ratio for all AREs was 0.50 (95% CI, 0.27-0.93; P = .03) (Table 2).
The tests for the proportional-hazards assumptions with Schoenfeld residuals gave χ 26 = 7.0 and
P = .32 for first ARE and χ 26 = 7.3 and P = .30 for all AREs.
Hospitalizations occurred in 2 participants (1.2%) in the AZM group (1.3 total events per 100
person-years) and 9 participants (5.2%) in the placebo group (7.1 total events per 100 person-years)
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Graphs show data for first acute respiratory exacerbation (A), all acute respiratory exacerbations (B), and all-cause hospitalizations (C). AZM indicates azithromycin.
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(Figure 2C and Table 2). The hazard ratio for hospitalizations was 0.24 (95% CI, 0.06-1.07; P = .06).
Death, infectious episodes (Salmonella typhi and gastroenteritis), and malaria were rare (Table 2).
There were 3 cases of tuberculosis, all in the placebo group (1 diagnosed through Xpert MTB/RIF, 1
diagnosed on chest radiography, and 1 patient with tuberculous meningitis who died). The mean (SD)
values of weight-for-age z score were −2.15 (1.40) in the AZM group and −1.94 (1.27) in the placebo
group. The AMD was 0.03 (95% CI using robust SE, −0.08 to 0.14; P = .56) higher in the AZM group
compared with the placebo group.
The results of subgroup analyses for the primary outcome are shown in Figure 3 and in eTable 4
in Supplement 2. The results showed no evidence for treatment-by-subgroup interaction.
Safety
There was a higher number of gastrointestinal symptoms in the AZM group compared with the
placebo group, but they were all minor (DAIDS grade <3), transient, and resolved spontaneously.
There were no cases of C. difficile infection. None of the severe adverse events was related to study
medication (eTable 3 in Supplement 2).
Discussion
This randomized clinical trial of an intervention to address HCLD in children found that once-weekly
AZM had no effect on the primary outcome of pulmonary function, but it was associated with a
reduced rate of AREs and increased time to first ARE compared with placebo. There were fewer
hospitalizations in the AZM group vs the placebo group but the difference was not significant. We
hypothesized that AZM would reduce systemic inflammation, which would translate into
improvement of lung function, and/or have an antibiotic effect. Inflammatory and other biomarkers
will be reported separately, but there was no evidence of improvement of pulmonary function in our
trial. In previous studies,30,31 a decrease in airway inflammation with AZM was observed in 40% of
patients with posttransplant OB, and inflammatory markers, including interleukin-8 and neutrophilia,
were associated with improvements in FEV1. The effect of AZM on lung function has been variable,
with no effect in patients with bronchiectasis (excluding cystic fibrosis) and an improvement at early
time points (up to 6 months) but not beyond in studies of patients with cystic fibrosis.18,32
The prophylactic antimicrobial effect of AZM on ARE reported here for HCLD is consistent with
trials of AZM in other chronic lung diseases among both children and adults, with a reduction in
pulmonary exacerbations and less-frequent need for antibiotics compared with patients receiving












Primary outcome, FEV1 z score at 48 wk, mean (SD) −1.90 (0.90) −1.95 (0.91) 0.06 (−0.10 to 0.21) .48 NA NA
Secondary outcomesc
Total episodes of ARE 19/157 38/154 NA NA 0.50 (0.27 to 0.93) .03
First ARE 16/148 30/139 NA NA 0.50 (0.27 to 0.92) .03
Death 0/157 3/154 NA NA NA NA
All-cause hospitalization 2/157 11/154 NA NA 0.24 (0.06 to 1.07) .06
Salmonella typhi infection 0/157 0/154 NA NA NA NA
Gastroenteritis 1/157 2/154 NA NA NA NA
Malaria 1/157 2/154 NA NA NA NA
Weight-for-age z score, mean (SD) −2.15 (1.38) −1.94 (1.27) 0.03 (−0.08 to 0.14) .56 NA NA
Abbreviations: AMD, adjusted mean difference; ARE, acute respiratory exacerbation;
AZM, azithromycin; FEV1, forced expiratory volume in 1 second; HR, hazard ratio; NA, not
applicable.
a Primary and secondary outcomes were assessed for 162 patients in the AZM group.
b Primary and secondary outcomes were assessed for 146 patients in the placebo group.
c Outcomes refer to number of participants per person-years of risk, unless stated
otherwise. Formal comparison of trial groups was not undertaken if fewer than 10
events overall or no events in 1 trial group.
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placebo.18,32 Studies2,3 from sub-Saharan Africa in the ART era have shown that HCLD affects up to
one-third of children; therefore, the present findings potentially have substantial implications in
terms of reduced antimicrobial use. Given the lack of diagnostic facilities, children with chronic
respiratory symptoms are often presumptively treated for tuberculosis, a common disease in
high-HIV prevalence settings.16,33 Major indirect benefits, such as less interrupted schooling,
improved quality of life, and reduced economic burden on the family, should also be evaluated.
Because of its broad-spectrum activity, AZM is also effective against pathogens that cause
diarrhea and malaria, including Salmonella species, which are a major cause of death in children living
with HIV.34 In trials evaluating mass drug administration of AZM for trachoma, there was a reduction
in all-cause child mortality, likely through AZM’s cumulative effect on reducing the risk of serious
infection from a range of pathogens.35 Data from our study showing reduced malaria, gastroenteritis,
and deaths in the AZM group are consistent with a decreased risk of these diseases, but with low
numbers of events. Because a mortality benefit is plausible, however, these data argue for additional
studies with larger sample sizes and longer follow-up.
The number of severe adverse events was higher in the placebo group than in the AZM group
and none was associated with AZM use. AZM was well-tolerated, with minor gastrointestinal adverse
effects that resolved without specific treatment. Previous trials18-20,36 have also shown that AZM is
remarkably safe, with nausea and diarrhea as the major adverse effects. A previous study37 reported
a prolonged QTc interval among older patients with a high prevalence of cardiac disease, with
potential for an estimated 0.047 additional deaths per 10 000 AZM courses. However, in the current
study, of the 3 participants discontinued from study medication because of a prolonged QTc interval,
2 were in the placebo group and all 3 were asymptomatic with no history of cardiac disease. This
reflects our conservative QTc interval threshold used for discontinuing study medication.
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As well as being safe and well-tolerated, the pharmacokinetics of AZM are unique, with high
intracellular uptake and slow hepatic excretion.38,39 The resulting high tissue concentrations made
once-weekly dosing feasible, possibly reducing nonadherence.
A concern with AZM is the emergence of antimicrobial resistance in the airway microbiome.
Studies18-20,40 have reported an increase in the proportion of macrolide-resistant commensal
oropharyngeal organisms, including when AZM is given as a single dose as part of mass
administration programs. Whether resistance persists and its clinical impact in individuals are not
clear; notably, colonization with macrolide-resistant organisms has not been associated with
increased exacerbations or a decline in pulmonary function.41 However, the potential of increase in
macrolide AZM resistance in bystander organisms and increase in prevalence of macrolide-resistant
organisms in the community is of public health concern.41 The potential for emergence of resistant
organisms is under investigation and will be reported separately.
These concerns justify the need for a selective approach to treatment. Future trials should
investigate AZM therapeutic effects against such factors as disease severity and pattern, functional
impairment, and extent of immunocompromise to identify patients who would gain most from such
an intervention.42 An additional question that remains to be answered is the sustainability of
treatment effect. We had intended to investigate outcomes at 72 weeks to investigate the durability
of treatment effect and persistence of resistance, but this was not feasible.
Strengths and Limitations
The trial was well-powered, achieved high rates of follow-up, and had consistent findings across
sensitivity analyses. The trial was conducted in public sector pediatric HIV clinics in 2 African
countries, which contributes to generalizability. The intervention was delivered over a full year, thus
reducing the seasonal factors associated with risk of ARE.
Limitations of the study include a higher loss to follow-up in the placebo than intervention
group. However, multiple imputation was performed, and we adjusted for baseline factors associated
with missing end line data. Spirometry is an operator-dependent procedure, and error in FEV1
measurement is possible. This was minimized through certified training and refresher training of
research staff and quality control assessment of spirometric traces to ensure that American Thoracic
Society standards were met. There was variance of FEV1 by age and potentially by trial group.
Although robust SEs were used, heteroscedasticity may have affected primary outcome estimates.
Furthermore, sustained adherence over a long period is challenging, particularly among the age
group under study.
Conclusions
Our trial found no difference in the primary outcome of lung function but showed that AZM is an
effective intervention in reducing ARE events associated with HCLD in children and adolescents.
AZM has previous proven efficacy for treating a variety of chronic lung diseases, is safe, and is well-
tolerated. Future research should identify patient groups who would benefit most from this
intervention, optimum treatment length and dosing schedules, and sustainability of
treatment effect.
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